What a New Meta-Analysis Found About Tirzepatide vs Semaglutide

What Did This New Tirzepatide vs Semaglutide Meta-Analysis Analyse?

Researcher Rodrigo Modesto Paccola and colleagues published a systematic review and meta-analysis in Clinical Obesity, a Wiley journal, comparing tirzepatide (a dual GIP/GLP-1 receptor agonist) directly against semaglutide (a GLP-1 receptor agonist) in adults with overweight or obesity.[1] Rather than relying on cross-trial comparisons of separately conducted studies, the authors pooled only head-to-head studies — trials and cohorts in which both compounds were assessed within the same population — with a minimum follow-up of 24 weeks.[1]

Because 7 of the 10 included studies were retrospective cohorts rather than randomised trials, the pooled result carries a higher risk of confounding than a purpose-built head-to-head RCT such as SURMOUNT-5. Its value lies in scale: at 41,381 participants, this is among the largest head-to-head comparisons of the two compounds assembled to date, and it is the first to pool serious-adverse-event data across that many records.

How Much More Weight Loss Did Tirzepatide Show?

The pooled analysis found tirzepatide associated with significantly greater percentage body-weight reduction than semaglutide: a mean difference of −4.28 percentage points (95% CI −5.28 to −3.28; P<0.00001).[1] In absolute terms, the mean difference was −4.43kg in favour of tirzepatide (95% CI −5.56 to −3.30; P<0.00001).[1]

The threshold data is a useful complement to the mean-difference figures: it shows the efficacy gap was not confined to a small shift in the population average, but extended to a higher probability of reaching clinically discussed weight-loss bands at every threshold above 5%.[1] That pattern is broadly consistent with the head-to-head margin reported in the earlier SURMOUNT-5 trial, which found roughly 20% mean reduction for tirzepatide against roughly 14% for semaglutide at 72 weeks under randomised, open-label conditions.

What Happened to Glycaemic Control?

HbA1c reduction was also significantly greater with tirzepatide across the pooled studies: mean difference −0.29% in favour of tirzepatide (P=0.0002).[1] This tracks with the compounds' underlying receptor pharmacology — tirzepatide's added GIP-receptor agonism sits alongside GLP-1 agonism shared with semaglutide, and GIP co-agonism has repeatedly been associated with incremental glycaemic and weight effects across the incretin literature, a mechanistic thread also explored in our retatrutide vs tirzepatide vs semaglutide comparison for the triple-agonist case.

Did Tirzepatide Show a Higher Rate of Serious Adverse Events?

The authors reported that overall adverse events and gastrointestinal adverse events specifically — nausea, diarrhoea, vomiting, constipation, the events that dominate incretin-class tolerability data — were similar between the two groups, and that there was no significant difference in treatment discontinuation due to adverse events.[1] In other words, the safety signal in this pooled dataset sits specifically in the serious-adverse-event category, not in the routine gastrointestinal tolerability profile both compounds are already known for.

A near-doubling of serious-adverse-event rate alongside a materially larger weight-loss effect is exactly the kind of trade-off a meta-analysis is built to surface: neither figure alone tells the full story, and reporting them together, as the authors did, gives a more complete picture than an efficacy headline in isolation.

How Does This Fit With Earlier Head-to-Head Data?

This 2026 pooled analysis sits alongside, rather than replaces, the randomised SURMOUNT-5 trial data that first established tirzepatide's head-to-head weight-loss margin over semaglutide under matched, prospective conditions. What this meta-analysis adds is scale and a safety lens: by pooling 41,381 records across 10 studies, including real-world retrospective cohorts alongside randomised data, it is better powered to detect a serious-adverse-event signal than any single trial in the dataset, at the cost of the confounding risk that comes with observational data.

Both compounds sit in the broader incretin research landscape our retatrutide vs tirzepatide vs semaglutide guide maps by receptor target, and the efficacy-versus-safety pattern reported here is a relevant reference point for anyone tracking how additional receptor agonism (GIP, and in retatrutide's case glucagon as well) trades off against tolerability across the class.

What Should UK Researchers Take From This?

For researchers tracking the incretin literature, this meta-analysis is a useful reference point on the current pooled evidence for tirzepatide's efficacy margin over semaglutide (weight loss, threshold achievement, HbA1c) set directly against its pooled serious-adverse-event rate. It reports on clinical and real-world data for two licensed medicines administered under medical supervision — a separate question from research-use compounds sold as laboratory reagents. It has no bearing on the UK regulatory status of research-use peptides; see our guide on whether research peptides are legal in the UK for that separate question.

Velox Peptides does not stock tirzepatide or semaglutide. The closest research compound in our catalogue is Retatrutide, the triple GIP/GLP-1/glucagon receptor agonist that extends the same GIP/GLP-1 mechanistic line this meta-analysis probes, supplied strictly as an HPLC-verified in vitro research reagent.

Tirzepatide and semaglutide are referenced here for research-news context only. Neither is sold by Velox Peptides. Where supplied by Velox Peptides, retatrutide is a research reagent, not a medicine, and has not been evaluated by the MHRA or FDA in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions